PATENT CLAIM ANALYSIS

Application Number: 15759305
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Claim (Index 25):
The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to  claim 23 , wherein the antisense oligomer (A) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 13 (NMS-17), SEQ ID NO: 76 (NMS-138), SEQ ID NO: 68 (NMS-120), SEQ ID NO: 75 (NMS-137), SEQ ID NO: 51 (NMS-76), SEQ ID NO: 52 (NMS-79), SEQ ID NO: 54 (NMS-81), SEQ ID NO: 55 (NMS-82), SEQ ID NO: 56 (NMS-83), SEQ ID NO: 53 (NMS-80), SEQ ID NO: 33 (NMS-49), SEQ ID NO: 63 (NMS-114), SEQ ID NO: 69 (NMS-124), SEQ ID NO: 70 (NMS-125), SEQ ID NO: 61 (NMS-110), SEQ ID NO: 31 (NMS-46), SEQ ID NO: 34 (NMS-50), SEQ ID NO: 50 (NMS-75), SEQ ID NO: 45 (NMS-67) and SEQ ID NO: 64 (NMS-115).

Metadata:
- Claim Count in Document: 8.0
- Percentile: 90.0
- Lexical Diversity: 1.38889
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15759267', '15314535', '14368307', '15122435', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8500566408510222
- 35 USC 102 Novelty (BERT): 0.5641994124606607
- Combined Prediction Score: 0.821470918011986
- Mean Citation Score: 427.308318
- Max Citation Score: 475.8151
- Similarity Product: 359.713966702795

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test